STUDY DESIGN AND METHODS:
In the first part of the study, measles antibody titers were measured in donor plasma samples collected in 2007, 2011, and 2017. In the second part, trough or steady-state serum levels of measles neutralizing antibody were measured in two studies of patients with primary immunodeficiency (PID) who were treated with intravenous (Study 1; N = 46) or subcutaneous (Study 2; N = 18) Ig replacement therapy, meeting previous requirements for lot potency (≥0.6 x US Reference Ig 176). Serum measles neutralizing antibody titers were then estimated for conditions in which the potency of the Ig replacement product was 0.48 or 0.30 x US Reference Ig 176.
RESULTS: Measles antibody titers in donated plasma
samples declined in donors born after 1963. In the two studies of patients with PID who were treated with intravenous or subcutaneous Ig replacement therapy, all patients exhibited trough (intravenous Ig) or steady-state (subcutaneous Ig) measles neutralizing antibody titers above 0.12 IU/mL, which has been shown to protect against clinical measles in the general population. Estimates suggest that all patients except one would have continued to meet this standard if the Ig lot potency had been 0.48 or 0.30 x US Reference Ig 176.
INTRODUCTION

I
ntravenous and subcutaneous immunoglobulin (Ig) products are the primary treatment for patients with primary immunodeficiency (PID) to protect them from frequent infection. Ig lots are required to satisfy minimum US Food and Drug Administration (FDA) standards for antibodies with demonstrated activity against measles, diphtheria, and poliovirus types 1, 2, or 3. These requirements were established to provide PID patients with immunologic protection against these pathogens, and presumably indicate that immunologic activity against other pathogens is retained through the manufacturing process. Before 2008, Ig lots were required to contain measles neutralizing antibody at titers 0.6 × the US Ig Reference, defined as Center for Biologics Evaluation and Research (CBER) standard lot 176. In 2008, the requirement for measles neutralizing antibody in marketed Ig lots was changed to 0.48 x US Ig Reference 176 to help manufacturers adapt to declining measles neutralizing antibody levels in donor plasma.
Individuals who have experienced naturally acquired measles infection in earlier life generally have higher serum titers of measles neutralizing antibody than those who have received a measles vaccine. incubator for 7-9 days. After this incubation, the plates were analyzed using an inverted light microscope. Wells showing any sign of cytopathic effect were considered positive. The 50% neutralization dose (defined as the sample dilution, at which the cytopathic effect is inhibited in 50% of test wells) was calculated using the Spearman-Kärber formula.
Lots of IgPro10 and IgPro20 used in the clinical studies were tested for measles antibody titer using hemaglutination inhibition tests relative to in-house reference material that was calibrated against US Ig Reference 176 and IS 66/202. Patient samples in the clinical study of IgPro10 were tested using a neutralizing antibody assay (see above) relative to US Ig Reference 176. Patient samples in the clinical study of IgPro20 were tested using a plaque-reduction neutralization test relative to US Ig Reference 176 and IS 66/202. 8 
ELISA
ELISA measurement of anti-measles IgG was performed using the ETI-Measles IgG Enzyme Immunoassay test kit (DiaSorin, Inc. Stillwater, Minnesota) and following the manufacturer's instructions, with the following exceptions. Samples were diluted 1:1000 rather than 1:100 as described in the kit. Furthermore, the assay was validated internally for use on plasma samples versus serum samples. In addition, the kit manufacturer's calibration curve was replaced by a calibration curve prepared using internal standards.
The internal standard had been tested against IS 97/648 using a neutralization assay.
PID study participants (Study 1 and Study 2)
Serum samples used for the current study had been retained from two prior clinical studies of intravenous Ig (IgPro10, Privigen) 9 or subcutaneous Ig (IgPro20, Hizentra) 10 products in patients with PID. Both studies were conducted in accordance with the International Conference on Harmonisation Good Clinical Practice guideline and the Declaration of Helsinki. Written Informed consent was obtained before the conduct of any study-related procedures. All study sites had institutional review board or independent ethics committee approval as required.
For those earlier studies, male or female participants from 4 to 71 (Study 1) or 2 to 75 (Study 2) years of age were eligible if they had a diagnosis of common variable immunodeficiency (CVID) or X-linked agammaglobulinemia (XLA). In addition, all participants were required to have received Ig therapy every 3-4 weeks for at least 3 months before study entry. During Study 1, participants received intravenous Ig (IgPro10) every 3 or 4 weeks. During Study 2, participants received weekly subcutaneous Ig (IgPro20). Both studies used Ig products approved in the United States, and the release of each lot was contingent on meeting the specification for measles neutralizing antibody in effect at the time (0.6 x US Ig Reference 176).
Serum measles antibodies in study participants
Serum samples were analyzed by the measles neutralization test (or NT) from 46 participants of Study 1 and 18 participants of Study 2. One participant in Study 1 was excluded because serum measles neutralizing antibody levels measured by ELISA were not proportional to the measlesspecific Ig dose. Most participants had only one NT assay performed during the study period; but when more than one NT assay was performed for an individual participant, only the first was used for the current analysis.
For both studies, serum samples were collected after at least 12 weeks of regular Ig replacement therapy. For the purposes of the current analysis, doses of Ig administered to individual participants were averaged over the 4 weeks preceding sample collection, and then converted to measles neutralizing antibody-specific doses (ref U/kg/week) using specific lot potencies (with regard to measles neutralizing antibodies) as assessed from release certificates. For example, for a participant who received 183.8 mg/kg subcutaneous Ig per week, using Ig with a lot potency of 1.4 x US Ig Reference 176, the measles neutralizing antibody-specific dose was 183.8 x 1.4/10 reference U/kg (1 reference Unit equals the measles neutralizing antibody content in 1 mL of 1% Reference Ig). The participant's serum measles neutralizing antibody titer was then plotted according to that participant's measles neutralizing antibody-specific monthly (Study 1) or weekly (Study 2) Ig dose, averaged during the 4 weeks preceding sample collection.
Calculation of
estimated serum measles neutralizing antibody titers for PID patients treated with hypothetical Ig lots of reduced lot potency Hypothetical serum antibody concentrations resulting from a lot potency of 0.30 or 0.48 x US Ig Reference 176 were calculated by proportional reduction of both the measlesspecific dose and the serum antibody concentration. This produced a more pronounced adjustment for samples obtained after dosing with lots of higher potency as compared with lots of lower potency.
RESULTS
Longitudinal declines in measles neutralizing antibody titers in donors
Measles antibody titers in donated plasma were measured by ELISA in 1169 individual donor samples obtained from 23 collection centers in the United States during August and September of 2017. Consistent with previous studies, 4, 5 plasma measles antibody titers were substantially higher in donors born before the introduction of the measles vaccine in 1963, compared with donors born after 1963 (Fig. 1) .
The results in Fig 1952  1954  1956  1958  1960  1962  1964  1966  1968  1970  1972  1974  1976  1978  1980  1982  1984  1986  1988  1990  1992  1994  1996 Fig. 2A ) and the NT (Fig. 2B ) assay. Results of ELISA and NT analyses are qualitatively similar. Plasma measles antibody titers are highest in donors in the older cohorts, who were more likely to have experienced naturally occurring measles infection. In the younger cohorts, in whom naturally occurring measles has become rare, plasma measles antibody titers are consistently lower. Note that by 2017, plasma measles antibody titers had begun to decline even in the oldest cohort (50-65 years of age), consistent with the expectation that measles vaccination is now affecting plasma measles antibody titers even in this oldest cohort of donors.
Measles-specific Ig lot potency required to maintain minimum serum measles neutralizing antibody titers in patients with PID
In both Study 1 (N = 46) and Study 2 (N = 18), participant ages varied widely: 4-66 years and 10-60 years, respectively. About 40%-60% of participants were female, and CVID was the most common PID-related diagnosis, accounting for about 80 and 94% of participants from the two studies, respectively. Other participants had been diagnosed with XLA.
During the study, all Ig lots administered to participants satisfied the requirement for the measles neutralizing antibody lot potency in effect at the time (0.6 x US Ig Reference 176). Among the patients included from Study 1, the range of intravenous Ig doses was 312-992 mg/kg/month; among patients included from Study 2, the range of subcutaneous Ig doses was 144-386 mg/kg/week. For data illustration purposes, the Ig doses administered to these participants were converted to measles-specific doses (see Methods). Fig. 3 shows serum measles neutralizing antibody titers in each participant plotted according to measlesspecific Ig dose. Trough levels are shown for patients treated with intravenous Ig (Fig. 3A) , and steady-state levels are shown for patients treated with subcutaneous Ig (Fig. 3B) . All participants had trough or steady-state measles neutralizing antibody titers that were substantially above levels previously shown to be protective against clinical measles (0.12 IU/mL). 6 To determine if Ig products with lower lot potency could maintain serum measles neutralizing antibody titers above 0.12 IU/mL, the clinical results shown in Fig. 3 were used to estimate expected serum titers for study participants under the hypothetical situation in which Ig lots had lower measles-specific potency (0.48 or 0.30 x US Ig Reference 176). The calculations are described in Materials and Methods. Results of these calculations are shown in Fig. 4 . In both Study 1 and Study 2, estimated serum measles neutralizing antibody titers remained above 0.12 IU/mL. The only exception was one patient in Study 1, who was not included because the measured measles neutralizing antibody titer appeared to be incorrect on the basis of multiple measurements taken after different Ig doses. These results provide supporting evidence that Ig products with lot potency of 0.30 x US Ig Reference 176 will protect most patients with PID from measles. measles neutralizing antibody level is used to indicate that the activity of all antibodies has been maintained during the manufacturing process. Consistent with previous studies, 4, 5 we have observed strong declines in measles neutralizing antibody titers in plasma from donors born after the introduction of the measles vaccine in 1963. The likely explanation for this decline is that measles vaccination induces lower titers of measles neutralizing antibody than does natural measles infection. This new steady state of measles neutralizing antibody titers in donated plasma presents a significant challenge to manufacturers of Ig products, who must produce Ig lots that meet minimum requirements for measles neutralizing antibody titers. This challenge has been recognized for some time, and was partially addressed in 2008, when the FDA lowered the minimum lot potency for measles neutralizing antibody in Ig products from 0.6 to 0.48 x US Ig Reference 176. Fortunately, epidemiology reports reviewed at the joint FDA-industry sponsored workshop (November 9-10, 2017) found no evidence that the lowered requirements for measles neutralizing antibody titers in Ig products has increased the risk of clinically evident measles among people with PID who are given replacement Ig products. Given the continued decline in measles antibody titers in plasma donors, the challenges of manufacturing Ig products that meet requirements for measles neutralizing antibody continue to increase.
It has been shown that a serum measles neutralizing antibody titer of 0.12 IU/mL provides protection against clinical measles in healthy individuals. 6 Unfortunately, it is not known what serum titers are needed to provide similar protection in people with PID. Given that PID comprises more than 300 distinct conditions, there is likely to be substantial variance in the minimum serum measles neutralizing antibody titers needed to prevent clinical measles. Furthermore, there is substantial variance in the pharmacokinetics and dosing of Ig replacement therapy across individual patients with PID. We tested serum measles neutralizing antibody titers in two studies of 46 and 18 people, respectively. The participants in the two studies all had PID and were treated with either intravenous or subcutaneous Ig products that exceeded the previous requirements for lot potency (0.6 x US Ig Reference 176). Study 1 evaluated trough measles neutralizing antibody titers in patients treated with intravenous Ig, and Study 2 evaluated steady-state measles neutralizing antibody titers in patients treated with subcutaneous Ig. Across both studies, all participants had maintained serum measles neutralizing antibody titers above 0.12 IU/mL. We then applied arithmetic adjustments intended to model serum measles neutralizing antibody levels in the same patients under conditions of reduced lot potency of the Ig replacement product. The results indicated that serum measles neutralizing antibody titers remained above 0.12 IU/mL at both trough levels (worst-case scenario for patients treated with intravenous Ig) and steady-state levels (in patients treated with subcutaneous Ig), even when the hypothetical lot potency of the Ig replacement was 0.30 x US Ig Reference 176. The only exception was one patient, not included in the analysis, who had an unusual pattern of serum measles antibody titers measured by ELISA, which was not proportional to measles neutralizing antibody titers in the Ig replacement product. Thus, we believe that this exception may not be caused by inadequate measles antibody in the patient's replacement Ig product. Furthermore, this participant's serum measles neutralizing antibody levels were measured at trough, so the possibility remains that even this one participant had adequate protection against measles during most of the treatment cycle. All participants who received subcutaneous Ig had estimated steady-state measles neutralizing antibody titers above 0.12 IU/mL in the calculations based on a lot potency of 0.30 x US Ig Reference 176.
Overall, the results suggest that a lot potency of 0.3 x US Ig Reference 176, with respect to measles neutralizing antibody, will be immunoprotective against clinical measles in most people receiving Ig replacement products at a dose of at least 100 mg/kg/week (subcutaneous) or 400 mg/kg/ month (intravenous). It should be noted, however, that Ig replacement products are used for a wide range of immunodeficiency disorders, some of which impair T-cell function. It is theoretically possible that Ig replacement products with lower titers of measles neutralizing antibodies may not prevent subclinical infection in patients with severely impaired T-cell function. Nevertheless, combining the donor and patient data, a lot release criterion of 0.30 x US Ig Reference 176 is proposed. The donor snapshots indicate that this level can be achieved for a number of years into the future, will provide patient protection, and will continue to indicate that antibody activity as well as antibody concentration is present in marketed Ig products.
